While some phytocannabinoids (“plant cannabinoids”), like CBN and THC, imitate the activity of endocannabinoids by binding directly to cannabinoid receptors in order to affect the body, scientists believe that CBD only binds weakly to cannabinoid receptors and instead affects the body indirectly.
One of the ways it does this is by occupying the site of enzymatic activity and preventing the enzyme FAAH from breaking down endocannabinoids like anandamide. By doing this, CBD indirectly increases endocannabinoid levels within the body, enabling them to continue supporting the function of the ECS, and contributing to the maintenance of a balanced and healthy internal state.
Moreover, if CBD is consumed along with traceable THC (e.g. in medical cannabis), the extended presence of anandamide and other endocannabinoids can in turn prevent THC from binding to cannabinoid receptors in the brain and producing a ‘high’. In this way, CBD may also indirectly counteract the intoxicating effects of THC.